Piedmont Investment Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-117,156
Closed -$7.37M 229
2020
Q1
$7.37M Buy
117,156
+58,944
+101% +$4.25M 0.29% 80
2019
Q4
$4.53M Buy
58,212
+2,469
+4% +$193K 0.16% 146
2019
Q3
$4.09M Buy
55,743
+702
+1% +$49.3K 0.16% 139
2019
Q2
$3.39M Sell
55,041
-654
-1% -$39.5K 0.14% 161
2019
Q1
$3.55M Buy
55,695
+819
+1% +$46.7K 0.14% 152
2018
Q4
$2.8M Sell
54,876
-51,717
-49% -$2.62M 0.13% 156
2018
Q3
$6.19M Buy
106,593
+44,253
+71% +$2.16M 0.26% 94
2018
Q2
$3.02M Buy
62,340
+10,647
+21% +$497K 0.15% 148
2018
Q1
$2.4M Buy
51,693
+40,482
+361% +$1.76M 0.06% 245
2017
Q4
$421K Buy
11,211
+21
+0.2% +$771 0.01% 461
2017
Q3
$408K Buy
11,190
+141
+1% +$5.38K 0.01% 479
2017
Q2
$435K Buy
+11,049
New +$403K 0.01% 451
2017
Q1
Sell
-1,824
Closed -$57K 479
2016
Q4
$57K Buy
1,824
+1,803
+8,586% +$58.4K ﹤0.01% 429
2016
Q3
$843 Hold
21
﹤0.01% 441
2016
Q2
$698 Buy
+21
New +$718 ﹤0.01% 395

Other funds holding EW

Piedmont Investment Advisors's EW Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Edwards Lifesciences (EW) in Q2 2020, closing a stake of 117,156 shares — an estimated $7.37M sold.

Piedmont Investment Advisors first reported a position in EW in Q2 2016 and held it in 15 quarters. The position peaked at $7.37M in Q1 2020. 1,047 funds tracked by Wall St. Rank hold EW as of Q2 2020.

  • Piedmont Investment Advisors reported no remaining Edwards Lifesciences position as of Q2 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 117,156 Edwards Lifesciences shares in Q2 2020, an estimated $7.37M.
  • Piedmont Investment Advisors first reported a position in Edwards Lifesciences in Q2 2016 and held it in 15 quarters.
  • Piedmont Investment Advisors's Edwards Lifesciences position peaked at $7.37M in Q1 2020.
  • 1,047 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.